Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
ID: 350264Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350264

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies for HIV that can be implemented at the initiation of combination antiretroviral therapy (cART) or upon restarting cART after treatment interruptions, with the ultimate goal of achieving sustained treatment-free remission. The program encourages interdisciplinary collaboration and participation from underrepresented groups, emphasizing the importance of advancing HIV cure research. Applications are due by December 7, 2023, and interested parties can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries. The funding is contingent on NIH appropriations, and proposals will be evaluated based on scientific merit and potential impact.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-297-Full-Announcement.html
    PAR-23-297.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Notice of Funding Opportunity (NOFO) titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation" (R01). This funding initiative aims to research new cure strategies for HIV that can be applied at the onset of combination antiretroviral therapy (cART) or upon restarting cART after treatment interruptions. The goal is to identify methods that lead to sustained treatment-free remission of HIV. Applications must adhere to strict guidelines and cannot involve clinical trials. Eligible applicants include various institutions such as higher education and nonprofit organizations, and all proposals will be evaluated based on scientific merit, significance, innovation, approach, and investigator qualifications. The review process will focus on the potential impact of the proposed research on the field of HIV treatment. Key dates include application submission deadlines starting December 7, 2023, with funding for meritorious projects contingent on NIH appropriations. This initiative emphasizes interdisciplinary collaboration and encourages participation from underrepresented groups to promote innovation and progress in HIV cure research.
    Similar Opportunities
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies that can be implemented at the onset of combination antiretroviral therapy (cART) or upon restarting cART after an analytical treatment interruption, with the ultimate goal of achieving sustained treatment-free remission. The NIH encourages multidisciplinary research approaches that enhance understanding of HIV dynamics and improve strategies for sustained remission, while excluding clinical trials. Interested applicants, including a diverse range of institutions such as historically black colleges, tribal governments, and community-based organizations, must submit their proposals by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html.
    Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)" aimed at supporting research on the impact of defective HIV proviruses on persistence and pathogenesis during antiretroviral treatment. The objective is to characterize these defective proviruses in human samples, optimize assays to mitigate their influence, and study their effects on viral dynamics, which is crucial for improving HIV cure strategies and understanding chronic immune activation in treated individuals. Eligible applicants include a wide range of institutions, such as public and private nonprofits, higher education entities, and for-profits, with funding available up to $500,000 per year for projects lasting a maximum of five years. Interested parties should note that applications can be submitted starting in April 2025, and all inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Martin Delaney Collaboratories for HIV Cure Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Martin Delaney Collaboratories for HIV Cure Research," aimed at advancing research strategies to control HIV replication and ultimately eradicate HIV reservoirs. This initiative seeks to foster collaborations among academic institutions, government scientists, the private sector, and community stakeholders to accelerate HIV cure research, particularly addressing the needs of children living with HIV. The estimated total program funding is $20 million, with six awards expected to be granted, and interested small businesses can reach out to Diane Lawrence, Ph.D., at diane.lawrence2@nih.gov or call 240-627-3202 for more information. Key deadlines include an estimated synopsis post date of April 21, 2026, and a close date of August 19, 2026, with awards anticipated by March 1, 2027.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive methods for HIV and associated complications. The primary objective of this grant is to facilitate the planning activities necessary for submitting an Investigational New Drug (IND) application to the FDA, with a focus on translating innovative research into effective drug products. This funding opportunity is particularly significant as it encourages collaboration among multidisciplinary teams to address critical health challenges related to HIV. Interested applicants can apply starting February 13, 2024, with a total funding amount of $1,000,000 anticipated for 2-3 awards in fiscal year 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-029.html.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)" under the National Institute of Mental Health (NIMH). This initiative aims to support innovative research focused on optimizing HIV prevention and care, emphasizing the understanding of behavioral and social science factors that influence the HIV continuum, including intervention efficacy trials and implementation science studies. The program is critical for advancing national efforts to address HIV effectively, promoting community engagement and multidisciplinary collaboration to achieve equitable health outcomes for diverse populations. Interested applicants can find more information and application details at the provided link, with a submission deadline of January 9, 2026, and no cost-sharing or matching requirements.
    Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed)." This funding initiative aims to support research focused on the HIV-1 Envelope (Env), specifically investigating its cell surface expression, the mechanisms of biologic-mediated cell killing, and the development of innovative strategies to enhance the recognition and elimination of HIV-infected cells. The research is critical for advancing immunotherapies and targeted vaccines for HIV-1 prevention and cure. Eligible applicants include a wide range of institutions, particularly those representing underrepresented groups, with applications due by January 7, 2028. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-300.html.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for HIV Pediatric, Adolescent and Maternal Clinical Trials
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on high-priority HIV studies targeting infants, children, adolescents, young adults, and maternal populations. This initiative aims to establish an HIV clinical trials network dedicated to these demographics, fostering innovative and collaborative clinical trials to address significant research areas in HIV and related health issues. The estimated total program funding is $30 million, with two awards anticipated, and potential applicants are encouraged to begin forming collaborations and developing proposals ahead of the expected synopsis posting on November 21, 2025. For further inquiries, interested parties may contact Dr. Sonia Lee at Sonia.lee@nih.gov or by phone at 301-594-4783.
    Implementation Science to End the HIV Epidemic
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Implementation Science to End the HIV Epidemic," aimed at advancing efforts to combat HIV through innovative research-community collaborations. The initiative seeks projects that will develop and evaluate strategies for HIV prevention, diagnosis, treatment, and outbreak response, particularly in communities disproportionately affected by the epidemic. This funding, totaling an estimated $7 million, will support approximately 10 awards, with applications open to a diverse range of eligible entities, including tribal governments, federal agencies, and community-based organizations. Interested applicants should note that the estimated synopsis close date is April 17, 2026, and the anticipated award date is December 1, 2026; for further inquiries, contact Rebecca Mandt, Ph.D., at rebecca.mandt@nih.gov or call 301-435-7695.